ACORDA THERAPEUTICS, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of June 23, 2014 to Indenture Dated as of June 23, 2014 1.75% Convertible Senior Notes due 2021First Supplemental Indenture • June 23rd, 2014 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
FIRST SUPPLEMENTAL INDENTURE dated as of June 23, 2014 (this “Supplemental Indenture”) between ACORDA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture dated as of June 23, 2014 between the Company and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
ACORDA THERAPEUTICS, INC.Acorda Therapeutics Inc • June 23rd, 2014 • Biological products, (no disgnostic substances) • New York
Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”) $300,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Underwritten Securities”) and, at the option of the Underwriter, up to an additional $45,000,000 principal amount of its 1.75% Convertible Notes due 2021 (the “Option Securities”) if and to the extent that the Underwriter shall have determined to exercise the option to purchase such 1.75% Convertible Notes due 2021 granted to the Underwriter in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities.” The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock (any shares of Common Stock issuable upon conversion of the Securities, including, for the avoidance of doubt, any additional shares deliverable upon conv
